Spiro Compounds Concept

subject area of

• Allosteric Modulation of the Dopamine D₂ Receptor by Pro-Leu-Gly-NH₂ Peptidomimetics Constrained in Either a Polyproline II Helix or a Type II β-Turn Conformation  Journal Articles
• Allosteric Modulation of the Dopamine Receptor by Conformationally Constrained Type VI β-Turn Peptidomimetics of Pro-Leu-Gly-NH₂  Journal Articles
• Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)^*  Journal Articles
• Armeniaspirols inhibit the AAA+ proteases ClpXP and ClpYQ leading to cell division arrest in Gram-positive bacteria  Journal Articles
• Chemical Screen for Vancomycin Antagonism Uncovers Probes of the Gram-Negative Outer Membrane  Journal Articles
• Design, Synthesis, and Dopamine Receptor Modulating Activity of Spiro Bicyclic Peptidomimetics ofl-Prolyl-l-leucyl-glycinamide  Journal Articles
• Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy  Journal Articles
• Metal-Induced Isomerization Yields an Intracellular Chelator that Disrupts Bacterial Iron Homeostasis  Journal Articles
• Pharmacological and immunocytochemical characterization of subtypes of alpha-1 adrenoceptors in dog aorta.  Journal Articles
• Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations  Journal Articles
• Rolapitant for the Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review of the Clinical Evidence  Journal Articles
• Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy  Journal Articles
• Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials  Journal Articles
• Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial  Journal Articles